Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Pearl Toh, 14 Nov 2020
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Drug-coated balloon angioplasty may be effective for infrapopliteal disease

Audrey Abella
05 Nov 2020

In patients with critical limb ischaemia (CLI) due to chronic total occlusions in the infrapopliteal region, drug-coated balloon (DCB) angioplasty was associated with a lower rate of late lumen loss compared with the standard balloon angioplasty – percutaneous transluminal angioplasty (PTA), according to the results of the IN.PACT below-the-knee (BTK) feasibility study presented at TCT 2020.

“DCB demonstrated effectiveness through 9 months vs PTA in a complex population,” said Dr Antonio Micari from the University of Messina, Italy, who presented the findings.

The study comprised 50 CLI patients (mean age 71 years, 78 percent male) with chronic total occlusions in the infrapopliteal arteries above the ankle (Rutherford class 4/5; single or multiple, with total lesion length ≥40 mm). Following successful vessel dilation (ie, ≤30 percent residual stenosis documented by angiographic visual estimate and functional duplex ultrasound assessment), participants were randomized 1:1 to receive either the IN.PACT 0.014 paclitaxel-coated DCB with a dose density of 3.5 μg/mm2, or conventional PTA. [TCT 2020, Endovascular 1: LBCT/LBCS session]

Nine months following the index procedure, there was a significantly lower rate of subsegmental late lumen loss with DCB vs PTA (mean, 0.59 vs 1.26 mm; p=0.017). A similar but nonsignificant trend was seen in terms of classic late lumen loss (mean, 0.89 vs 1.31 mm; p=0.070).

It is important to note that there were similar baseline lesion lengths and calcifications in both the DCB and PTA arms (215.41 and 218.19 mm; p=0.806 [length] and 54.1 percent and 41.4 percent; p=0.410 [calcification]). “These were very long and calcified lesions … The subsegmental measurement [at 9 months] showed a difference in the burden of restenosis in the two groups,” said Micari.

In the subsegmental method, measurements are taken along the entire lesion length, allowing for better assessment of late lumen loss. Whereas in the classic method, the measurement is obtained only at a single point in the lesion, explained Micari. “[Though] more rigorous, [the subsegmental method] can provide more feedback on how lesions failed over time,” he pointed out.

Safety-wise, the DCB and PTA arms had similar rates of the composite* safety endpoint (91.3 percent vs 87.5 percent; p=1.00). The rates of all-cause death were low (4.3 percent vs 8.0 percent), as were the rates of thrombosis at the target lesion site (4.3 percent vs 4.2 percent; p=1.00 for both).

“We purposefully included the most challenging lesions to reflect real-world CLI patients,” noted Micari. However, as the trial was underpowered, definitive conclusions cannot be made as to the role of DCB angioplasty for infrapopliteal disease.

Nonetheless, Micari expressed the study team’s plan of following through the patients for up to 3 or even 5 years to evaluate the mid- and long-term effects. “For now, we are happy to show that even in a small population, we have a difference … We are definitely looking forward to a bigger trial; we will enrol more patients and do a randomized study to give more sense to this data.”

“[Moreover, our study] provides an opportunity to affect future BTK studies and treatment algorithms,” he added.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Pearl Toh, 14 Nov 2020
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.